JP2013523846A5 - - Google Patents

Download PDF

Info

Publication number
JP2013523846A5
JP2013523846A5 JP2013504075A JP2013504075A JP2013523846A5 JP 2013523846 A5 JP2013523846 A5 JP 2013523846A5 JP 2013504075 A JP2013504075 A JP 2013504075A JP 2013504075 A JP2013504075 A JP 2013504075A JP 2013523846 A5 JP2013523846 A5 JP 2013523846A5
Authority
JP
Japan
Prior art keywords
compound
compound according
disorder
condition
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2013504075A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013523846A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2011/000390 external-priority patent/WO2011127565A1/en
Publication of JP2013523846A publication Critical patent/JP2013523846A/ja
Publication of JP2013523846A5 publication Critical patent/JP2013523846A5/ja
Ceased legal-status Critical Current

Links

JP2013504075A 2010-04-16 2011-04-08 タンパク質チロシンキナーゼ活性の阻害剤および眼部の障害を治療するためのそれらの使用 Ceased JP2013523846A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32480310P 2010-04-16 2010-04-16
US61/324,803 2010-04-16
PCT/CA2011/000390 WO2011127565A1 (en) 2010-04-16 2011-04-08 Inhibitors of protein tyrosine kinase activity and use thereof to treat ophthalmic disorders

Publications (2)

Publication Number Publication Date
JP2013523846A JP2013523846A (ja) 2013-06-17
JP2013523846A5 true JP2013523846A5 (enExample) 2014-05-15

Family

ID=44788641

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013504075A Ceased JP2013523846A (ja) 2010-04-16 2011-04-08 タンパク質チロシンキナーゼ活性の阻害剤および眼部の障害を治療するためのそれらの使用
JP2013504076A Ceased JP2013525286A (ja) 2010-04-16 2011-04-08 タンパク質チロシンキナーゼ活性の阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013504076A Ceased JP2013525286A (ja) 2010-04-16 2011-04-08 タンパク質チロシンキナーゼ活性の阻害剤

Country Status (19)

Country Link
US (3) US8906852B2 (enExample)
EP (2) EP2563794A4 (enExample)
JP (2) JP2013523846A (enExample)
KR (2) KR20130058006A (enExample)
CN (2) CN102947315A (enExample)
AR (2) AR080871A1 (enExample)
AU (2) AU2011241422B2 (enExample)
CA (2) CA2796008A1 (enExample)
CO (2) CO6640224A2 (enExample)
EA (2) EA201291052A1 (enExample)
MX (2) MX2012012031A (enExample)
MY (1) MY157319A (enExample)
NZ (2) NZ602954A (enExample)
PH (2) PH12012502070A1 (enExample)
SG (2) SG184883A1 (enExample)
TW (2) TW201204735A (enExample)
UA (1) UA108878C2 (enExample)
WO (2) WO2011127567A1 (enExample)
ZA (2) ZA201207482B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2183254B1 (en) * 2007-08-29 2017-06-21 MethylGene Inc. Inhibitors of protein tyrosine kinase activity
MX2010009729A (es) * 2008-03-05 2010-12-21 Methylgene Inc Inhibidores de actividad de proteina tirosina quinasa.
MX2012012031A (es) * 2010-04-16 2012-12-17 Methylgene Inc Inhibidores de la actividad de la proteina tirosina quinasa y uso de los mismos para tratar transtornos oftalmicos.
US20130090327A1 (en) * 2011-09-30 2013-04-11 Methylgene Inc. Inhibitors of Protein Tyrosine Kinase Activity
WO2013044361A1 (en) * 2011-09-30 2013-04-04 Methylgene Inc. Inhibitors of protein tyrosine kinase activity
US20130096135A1 (en) * 2011-09-30 2013-04-18 Methylgene Inc. Selected Inhibitors of Protein Tyrosine Kinase Activity
ES2593533T3 (es) 2011-12-15 2016-12-09 Pfizer Limited Derivados de sulfonamida
EP3200589B1 (en) 2014-09-10 2026-03-11 Temple University Of The Commonwealth System Of Higher Education Novel 5-hydroxytryptamine receptor 7 activity modulators and their method of use
US20180221365A1 (en) * 2015-05-12 2018-08-09 Temple University-Of The Commonwealth System Of Higher Education Novel sigma-2 receptor binders and their method of use
JP6664170B2 (ja) * 2015-08-31 2020-03-13 広栄化学工業株式会社 アミノヒドロキシピリジン化合物の製造方法
CN108530464B (zh) * 2017-03-02 2020-10-27 深圳海王医药科技研究院有限公司 一种多靶点激酶抑制剂
CN121108077A (zh) * 2025-09-02 2025-12-12 领泰生物医药(绍兴)有限公司 一种含氮杂环化合物的制备方法及其中间体

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050020619A1 (en) * 2003-07-24 2005-01-27 Patrick Betschmann Thienopyridine kinase inhibitors
EP1781664B1 (en) * 2004-07-30 2013-09-04 MethylGene Inc. Inhibitors of vegf receptor and hgf receptor signaling
AU2006229343A1 (en) * 2005-03-28 2006-10-05 Kirin Pharma Kabushiki Kaisha Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-Met autophosphorylation inhibiting potency
JO2787B1 (en) * 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
MX2007014617A (es) * 2005-05-20 2008-02-11 Methylgene Inc Inhibidores de senalizacion de receptor de factor de crecimiento endotelial bascular y receptor de factor de crecimiento de hepatocitos.
WO2008041053A2 (en) 2005-05-20 2008-04-10 Methylgene, Inc. Inhibitors of vegf receptor and hgf receptor signaling
EP2183254B1 (en) * 2007-08-29 2017-06-21 MethylGene Inc. Inhibitors of protein tyrosine kinase activity
WO2009026720A1 (en) * 2007-08-29 2009-03-05 Methylgene Inc. Processes and intermediates for preparing fused heterocyclic kinase inhibitors
MX2010009729A (es) * 2008-03-05 2010-12-21 Methylgene Inc Inhibidores de actividad de proteina tirosina quinasa.
MX2012012031A (es) * 2010-04-16 2012-12-17 Methylgene Inc Inhibidores de la actividad de la proteina tirosina quinasa y uso de los mismos para tratar transtornos oftalmicos.
WO2013044361A1 (en) * 2011-09-30 2013-04-04 Methylgene Inc. Inhibitors of protein tyrosine kinase activity

Similar Documents

Publication Publication Date Title
JP2015523546A5 (enExample)
PH12015501942A1 (en) Susbtituted 3-phenylpropylamine derivatives for the treatment of opthalmic diseases and disorders
JP2016505637A5 (enExample)
JP2013526544A5 (enExample)
RU2016151420A (ru) Новое терапевтическое применение производных бензилиденгуанидина для лечения протеинопатий
IN2014CN00989A (enExample)
JP2016515561A5 (enExample)
JP2014511891A5 (enExample)
JP2015511958A5 (enExample)
WO2013174930A3 (en) 7-oxo-thiazolopyridine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
MX2017013483A (es) Compuestos y su uso como inhibidores de ?-secretasa 1 (bace1).
JP2016540749A5 (enExample)
JP2013500977A5 (enExample)
JP2013522326A5 (enExample)
BR112014008759A2 (pt) tratamento de doença ocular
WO2013166037A9 (en) Non-retinoid antagonists for treatment of eye disorders
JP2016027060A5 (enExample)
JP2016522254A5 (enExample)
AR062395A1 (es) Uso de derivados del 2.5-dihidroxibenceno para el tratamiento de enfermedades oculares
JP2021503449A5 (enExample)
JP2019529514A5 (enExample)
CN111526878A (zh) 含三萜类化合物的药物组合物及其用途
HK1212688A1 (zh) 吡啶酮衍生物及其在治疗、改善或预防病毒疾病中的用途
JP2017505809A5 (enExample)
JP2017525758A5 (enExample)